Literature DB >> 9916775

Morsellized bone grafting compensates for femoral bone loss in revision total knee arthroplasty. An experimental study.

C J van Loon1, M C de Waal Malefijt, N Verdonschot, P Buma, A J van der Aa, R Huiskes.   

Abstract

This study was undertaken to examine the contribution of uncontained morsellized bone graft to the structural properties of a femoral reconstruction in total knee arthroplasty and to serve as a basis for an in vivo animal study. Ten human distal femora with a standard unicondylar uncontained medial bone defect were prepared to fit a femoral component of a cruciate sacrificing TKA. A cyclic axial load of 750 N was applied to the medial part of the femoral component in the presence of impacted morsellized bone graft. After removal of the bone graft, the cyclic loading was repeated for the unsupported situation. None of the grafts collapsed and all cement mantles stayed intact during the experiments. Elastic deformation during cyclic loading was significantly less when graft was added while time-dependent deformation was not affected. We conclude that impacted morsellized bone graft, used for reconstruction of uncontained femoral bone loss in revision knee arthroplasty, may improve the structural resistance against loading. Further animal experimentation for in vivo application is warranted.

Entities:  

Mesh:

Year:  1999        PMID: 9916775     DOI: 10.1016/s0142-9612(98)00155-0

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  2 in total

1.  Tissue engineering applications in the management of bone loss.

Authors:  Christian Carulli; Fabrizio Matassi; Roberto Civinini; Massimo Innocenti
Journal:  Clin Cases Miner Bone Metab       Date:  2013-01

2.  A sliding stem in revision total knee arthroplasty provides stability and reduces stress shielding.

Authors:  Huub J Meijerink; Corné J M van Loon; Maarten C de Waal Malefijt; Albert van Kampen; Nico Verdonschot
Journal:  Acta Orthop       Date:  2010-06       Impact factor: 3.717

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.